Cart
0

Human Chorionic Gonadotropin (hCG) Market by Technology (Natural Source Extraction, and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), and End User (Fertility Clinics, Research Institutes, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025

Get 20% Free Customization In This Report
LI_183418
Pages: 197
Sep 2018 | 1878 Views
 
Author's : Tanvi Sapatnekar, Kavita Joshi, & Onkar Sumant
Tables: 104
Charts: 32
 

Human Chorionic Gonadotropin (hCG) Market Overview:

The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. Human chorionic gonadotropin (hCG) belongs to the family of gonadotropin hormones and is naturally produced by the placenta. hCG hormone plays a pivotal role after the formation of the embryo, and hence has gained significant traction over the years for the treatment of infertility in women and men. hCG triggers ovulation in women and assists in increasing the sperm count in men.

The global hCG market is segmented based on technology, therapeutic area, end user, and region. By technology, the market is bifurcated into natural source extraction and recombinant technology. Based on therapeutic area, it is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Depending on end user, it is segregated into fertility clinics, research institutions, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Rise in the incidence of male hypogonadism among the geriatric population is the key factor driving the market growth. In addition, increase in traction gained by hCG among healthcare professionals and patients would supplement the market growth. However, cautions and warnings issued by the FDA pertaining to the side effects of hCG therapy is expected to hamper the market growth. Moreover, untapped economies are set to offer lucrative opportunities for the expansion of the hCG market.

Get more information on this report : Request Sample Pages

Technology Segment Review

Based on technology, the global human chorionic gonadotropin (hCG) market is bifurcated into natural source extraction and recombinant technology. The natural source extraction segment accounted for a major share in the global market in 2017 and is expected to maintain its dominance throughout the forecast period. The key players operating in the hCG industry exhibit a strong demand for gonadotropins obtained from natural sources, which marks a significant trend in the market over the recent years, which has largely contributed to the revenue generated by this segment. For instance, Sanzyme Ltd. offers gonadotropins that are extracted from natural sources. However, the recombinant technology segment is expected to register the highest growth rate from 2018 to 2025, owing to the availability of recombinant hCGs in different dose strengths, which provides an opportunity for individualized therapy.

Get more information on this report : Request Sample Pages

Therapeutic Area Segment Review

Depending on therapeutic area, the global human chorionic gonadotropin (hCG) market is categorized into female infertility treatment, oligospermic treatment, male hypogonadism, and others. The paradigm shift toward gonadotropin therapy for the treatment of several threatening diseases such as infertility, cryptorchidism, and others is expected to create lucrative opportunities for the expansion of the global hCG market. The female infertility segment dominated the global market in 2017 and is anticipated to remain dominant throughout the forecast period. This is attributed to the rise in infertility-related problems such as polycystic ovary syndrome (PCOS) in females. However, the male hypogonadism segment is expected to grow at the highest rate during the forecast period, due to increase in demand for hCG therapy in males suffering from hypogonadism across the globe.

Get more information on this report : Request Sample Pages

Region Segment Review

Based on region, the global human chorionic gonadotropin (hCG) market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the major revenue contributor in 2017 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to significant increase in incidence of infertility-related problems both in male and females. According to the Centers of Disease Control and Prevention, 12.1% of women aged 15‐44 years in North America suffer from impaired fecundity annually. Asia-Pacific is expected to possess the maximum market growth rate, due to growth in population, rise in awareness toward heath consciousness, increase in affordability, and improvement in healthcare facilities.

The major companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., Ferring B.V., Fresenius Kabi AG, Cigna, Sun Pharmaceutical Industries Ltd, Lee BioSolutions Inc., Sanzyme, Scripps Laboratories, and Lupin AB. The other players operating in the global human chorionic gonadotropin (hCG) market include Kamiya Biomedical Company, Intas Pharmaceuticals, Prospec-Tany Technogene Ltd., Cipla Limited, Biocare Medical, LLC, MyBioSource, Zydus Cadila, and Life Medicare & Biotech Pvt. Ltd.

Key Benefits for Stakeholders

  • The study provides an in-depth analysis along with the current trends and future estimations of the global human chorionic gonadotropin (hCG) market to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided.
  • The quantitative analysis of the industry from 2017 to 2025 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • An extensive analysis of key segments of the industry is provided to understand the technology and therapeutic area of human chorionic gonadotropin (hCG) applied globally.
  • The key players and their strategies are analyzed to understand the competitive outlook of the market.

Human Chorionic Gonadotropin (hCG) Market Key Segments:

By Technology

  • Natural Source Extraction
  • Recombinant Technology

By Therapeutic Area

  • Female Infertility Treatment
  • Male Hypogonadism
  • Oligospermic Treatment
  • Others

By End User

  • Fertility Clinics
  • Research Institutions
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key market benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Porter’s five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. High risk of hypogonadism in geriatric population
3.5.1.2. Rise in infertility rates
3.5.1.3. Increase in awareness toward hCG among healthcare professionals and patients

3.5.2. Restraints

3.5.2.1. Availability of substitutes
3.5.2.2. Cautions & warnings issued by FDA against the side effects of hCG

3.5.3. Opportunity

3.5.3.1. Rise in popularity of fertility tourism

Chapter: 4: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY

4.1. Overview

4.1.1. Market size and forecast

4.2. Natural source extraction

4.2.1. Key trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Recombinant technology

4.3.1. Key trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

Chapter: 5: HUMAN CHORIONIC GONADOTROPIN MARKET, BY THERAPEUTIC AREA

5.1. Overview

5.1.1. Market size and forecast

5.2. Female infertility treatment

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Oligospermic treatment

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Male hypogonadism

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Others

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

Chapter: 6: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Fertility clinics

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Research institutes

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Others

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

Chapter: 7: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key trends and opportunities
7.2.2. North America market size and forecast, by country

7.2.2.1. U.S. market size and forecast, by technology
7.2.2.2. U.S. market size and forecast, by therapeutic area
7.2.2.3. U.S. market size and forecast, by end user
7.2.2.4. Canada market size and forecast, by technology
7.2.2.5. Canada market size and forecast, by therapeutic area
7.2.2.6. Canada market size and forecast, by end user
7.2.2.7. Mexico market size and forecast, by technology
7.2.2.8. Mexico market size and forecast, by therapeutic area
7.2.2.9. Mexico market size and forecast, by end user

7.2.3. North America market size and forecast, by technology
7.2.4. North America market size and forecast, by therapeutic area
7.2.5. North America market size and forecast, by end user

7.3. Europe

7.3.1. Key trends and opportunities
7.3.2. Europe market size and forecast, by country

7.3.2.1. Germany market size and forecast, by technology
7.3.2.2. Germany market size and forecast, by therapeutic area
7.3.2.3. Germany market size and forecast, by end user
7.3.2.4. UK market size and forecast, by technology
7.3.2.5. UK market size and forecast, by therapeutic area
7.3.2.6. UK market size and forecast, by end user
7.3.2.7. France market size and forecast, by technology
7.3.2.8. France market size and forecast, by therapeutic area
7.3.2.9. France market size and forecast, by end user
7.3.2.10. Rest of Europe market size and forecast, by technology
7.3.2.11. Rest of Europe market size and forecast, by therapeutic area
7.3.2.12. Rest of Europe market size and forecast, by end user

7.3.3. Europe market size and forecast, by technology
7.3.4. Europe market size and forecast, by therapeutic area
7.3.5. Europe market size and forecast, by end user

7.4. Asia-Pacific

7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by country

7.4.2.1. Japan market size and forecast, by technology
7.4.2.2. Japan market size and forecast, by therapeutic area
7.4.2.3. Japan market size and forecast, by end user
7.4.2.4. China market size and forecast, by technology
7.4.2.5. China market size and forecast, by therapeutic area
7.4.2.6. China market size and forecast, by end user
7.4.2.7. India market size and forecast, by technology
7.4.2.8. India market size and forecast, by therapeutic area
7.4.2.9. India market size and forecast, by end user
7.4.2.10. Australia market size and forecast, by technology
7.4.2.11. Australia market size and forecast, by therapeutic area
7.4.2.12. Australia market size and forecast, by end user
7.4.2.13. Rest of Asia-Pacific market size and forecast, by technology
7.4.2.14. Rest of Asia-Pacific market size and forecast, by therapeutic area
7.4.2.15. Rest of Asia-Pacific market size and forecast, by end user

7.4.3. Asia-Pacific market size and forecast, by technology
7.4.4. Asia-Pacific market size and forecast, by therapeutic area
7.4.5. Asia-Pacific market size and forecast, by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA market size and forecast, by country

7.5.2.1. Brazil market size and forecast, by technology
7.5.2.2. Brazil market size and forecast, by therapeutic area
7.5.2.3. Brazil market size and forecast, by end user
7.5.2.4. Turkey market size and forecast, by technology
7.5.2.5. Turkey market size and forecast, by therapeutic area
7.5.2.6. Turkey market size and forecast, by end user
7.5.2.7. Saudi Arabia market size and forecast, by technology
7.5.2.8. Saudi Arabia market size and forecast, by therapeutic area
7.5.2.9. Saudi Arabia market size and forecast, by end user
7.5.2.10. South Africa market size and forecast, by technology
7.5.2.11. South Africa market size and forecast, by therapeutic area
7.5.2.12. South Africa market size and forecast, by end user
7.5.2.13. Rest of LAMEA market size and forecast, by technology
7.5.2.14. Rest of LAMEA market size and forecast, by therapeutic area
7.5.2.15. Rest of LAMEA market size and forecast, by end user

7.5.3. LAMEA market size and forecast, by technology
7.5.4. LAMEA market size and forecast, by therapeutic area
7.5.5. LAMEA market size and forecast, by end user

Chapter: 8: COMPANY PROFILES

8.1. Bristol Myers Squibb Company

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance

8.2. Ferring Pharmaceuticals Inc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio

8.3. Merck & Co., Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance

8.4. Fresenius Kabi AG

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance

8.5. Cigna

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance

8.6. Sun Pharmaceutical Industries Ltd.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. Lee BioSolutions Inc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio

8.8. Sanzyme

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio

8.9. Scripps Laboratories

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio

8.10. LUPIN

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 02. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR NATURAL SOURCE EXTRACTION, BY REGION, 2017-2025 ($MILLION)
TABLE 03. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RECOMBINANT TECHNOLOGY, BY REGION, 2017-2025 ($MILLION)
TABLE 04. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 05. HUMAN CHORIONIC GONADOTROPIN MARKET FOR FEMALE INFERTILITY TREATMENT, BY REGION, 2017-2025 ($MILLION)
TABLE 06. HUMAN CHORIONIC GONADOTROPIN MARKET FOR OLIGOSPERMIC TREATMENT, BY REGION, 2017-2025 ($MILLION)
TABLE 07. HUMAN CHORIONIC GONADOTROPIN MARKET FOR MALE HYPOGONADISM, BY REGION, 2017-2025 ($MILLION)
TABLE 08. HUMAN CHORIONIC GONADOTROPIN MARKET FOR OTHERS, BY REGION, 2017-2025 ($MILLION)
TABLE 09. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 10. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR FERTILITY CLINICS, BY REGION, 2017-2025 ($MILLION)
TABLE 11. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RESEARCH INSTITUTES, BY REGION, 2017-2025 ($MILLION)
TABLE 12. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR OTHERS, BY REGION, 2017-2025 ($MILLION)
TABLE 13. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 14. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 15. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 16. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 17. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 18. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 19. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 20. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 21. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 22. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 23. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 24. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 25. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 26. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 27. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 28. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 29. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 30. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 31. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 32. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 33. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 34. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 35. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 36. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 37. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 38. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 39. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 40. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 41. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 42. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 43. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 44. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 45. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 46. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 47. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 48. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 49. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 50. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 51. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 52. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 53. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 54. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 55. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 56. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 59. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 60. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 61. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 62. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 63. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 64. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 65. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 66. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 67. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 68. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 69. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 70. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 71. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 72. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 73. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 74. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 75. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 76. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 77. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 78. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)
TABLE 79. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)
TABLE 80. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 81. BRISTOL MYERS: COMPANY SNAPSHOT
TABLE 82. FERRING: COMPANY SNAPSHOT
TABLE 83. FERRING: OPERATING SEGMENTS
TABLE 84. FERRING: PRODUCT PORTFOLIO
TABLE 85. MERCK: COMPANY SNAPSHOT
TABLE 86. MERCK: OPERATING SEGMENTS
TABLE 87. MERCK: PRODUCT PORTFOLIO
TABLE 88. FRESENIUS: COMPANY SNAPSHOT
TABLE 89. FRESENIUS: PRODUCT PORTFOLIO
TABLE 90. CIGNA: COMPANY SNAPSHOT
TABLE 91. CIGNA: OPERATING SEGMENTS
TABLE 92. SUN PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 93. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 94. LEE: COMPANY SNAPSHOT
TABLE 95. LEE: PRODUCT SEGMENTS
TABLE 96. LEE: PRODUCT PORTFOLIO
TABLE 97. SANZYME: COMPANY SNAPSHOT
TABLE 98. SANZYME: PRODUCT SEGMENTS
TABLE 99. SANZYME: PRODUCT PORTFOLIO
TABLE 100. SCRIPPS: COMPANY SNAPSHOT
TABLE 101. SCRIPPS: PRODUCT SEGMENTS
TABLE 102. SCRIPPS: PRODUCT PORTFOLIO
TABLE 103. LUPIN: COMPANY SNAPSHOT
TABLE 104. LUPIN: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS, 2017
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. HIGH BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTION
FIGURE 07. HIGH THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE COMPETITIVE RIVALRY
FIGURE 09. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR NATURAL SOURCE EXTRACTION, BY COUNTRY, 2017 & 2025 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RECOMBINANT TECHNOLOGY, BY COUNTRY, 2017 & 2025 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR FEMALE INFERTILITY TREATMENT, BY COUNTRY, 2017 & 2025 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR OLIGOSPERMIC TREATMENT, BY COUNTRY, 2017 & 2025 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR MALE HYPOGONADISM, BY COUNTRY, 2017 & 2025 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR OTHERS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2017 & 2025 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR OTHERS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 19. BRISTOL-MYERS SQUIBB: REVENUE, 2015-2017 ($MILLION)
FIGURE 20. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 21. MERCK: REVENUE, 2015-2017 ($MILLION)
FIGURE 22. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 23. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 24. FRESENIUS: REVENUE, 2015-2017 ($MILLION)
FIGURE 25. FRESENIUS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26. FRESENIUS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. CIGNA: NET SALES, 2016-2018 ($MILLION)
FIGURE 28. CIGNA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. LUPIN: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. LUPIN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

The adoption of hCG treatment is expected to increase during the forecast period, due to rise in infertile population across the world and growth in awareness toward assisted reproductive technology among the developing countries. Use of recombinant technology in the production of (r-HCG) and rise in adoption of in vitro fertilization in the developing countries are the factors expected to boost the market growth during the forecast period. Other factors such as increase in success rate of hCG therapy in the developing economies across Asia-Pacific such as Malaysia & Thailand, surge in disposable income across the globe, and increase in trend of delayed pregnancies are expected to supplement the market growth in the near future. However, side effects associated with the use of hCG and FDA warnings for its vigorous use in weight loss are expected to hinder the market growth.

The key players operating in the human chorionic gonadotropin industry have maintained their market position by expanding their product portfolio through acquisitions. For instance, one of the most popular hCG brands, Pregnyl was originally manufactured by Organon Ltd. and later acquired by Merck. Moreover, vast product portfolio of hCG available in different strengths (concentrations) applied across various treatments of individuals suffering from infertility, high investment in R&D, and strong distribution networks observed by the key players are the factors that fuel the demand for hCG over the years.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Human Chorionic Gonadotropin (hCG) Market- Global Opportunity Analysis and Industry Forecast, 2017-2025

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4565
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5160
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $6747
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo